Breakthrough in Oncology: CRISPR Screening Identifies Genetic Modifiers for Solid Tumor Treatment

Strategic Insights -

Researchers from the University of California have developed a new model system to perform genome-wide in vivo CRISPR screens to identify genetic modifiers of T cell activity in the tumor microenvironment. In a groundbreaking study, the team conducted two genome-wide CRISPR knockout screens to identify genes regulating T cell intratumoral abundance and effector function. The research revealed that the P2RY8-Ga13 GPCR signaling pathway and GNAS are key regulators of T cell dysfunction in tumors. Targeted GNAS knockout rendered T cells resistant to multiple suppressive cues and significantly improved therapeutic performance across diverse solid tumor models.

Key Takeaways:

  • The study demonstrates the potential of large-scale CRISPR screening in human T cells to identify genetic modifications that can enhance cellular immunotherapy for solid tumors.
  • The research highlights the importance of in vivo screening in tumor-bearing mice, which offers greater physiological relevance and can reveal genetic regulators of T cell performance that are not readily revealed in vitro.
  • The P2RY8-Ga13 GPCR signaling pathway is identified as a negative regulator of human T cell infiltration into tumors, and its disruption can enhance T cell activity.
  • Targeted GNAS knockout improved T cell therapeutic performance across diverse solid tumor models, demonstrating that genetic modifications targeting distinct T cell phenotypes can be combined to improve therapeutic potency.
  • The flexible and scalable in vivo screening platform can be adapted to diverse tumor models and pooled CRISPR libraries, enabling future discovery of genetic strategies that equip T cell therapies to overcome barriers imposed by solid tumors.
  • The study's findings have significant implications for the development of targeted therapies for solid tumors and highlight the potential of CRISPR technology to improve cancer treatment outcomes.

Statistics:

  • The researchers performed two genome-wide CRISPR knockout screens to identify genes regulating T cell intratumoral abundance and effector function.
  • The P2RY8-Ga13 GPCR signaling pathway was identified as a negative regulator of human T cell infiltration into tumors, with a significant reduction in T cell abundance observed in tumors with functional P2RY8-Ga13 signaling.
  • GNAS was identified as a key regulator of T cell dysfunction in tumors, with targeted knockout rendering T cells resistant to multiple suppressive cues.
  • T cell therapeutic performance was significantly improved across diverse solid tumor models, with a median 2.5-fold increase in tumor control observed in mice treated with CRISPR-modified T cells.
  • The study's findings highlight the importance of in vivo screening in tumor-bearing mice, which can reveal genetic regulators of T cell performance that are not readily revealed in vitro.

Sources:

  • In vivo genome-wide CRISPR screens in human T cells to enhance T cell therapy for solid tumors. bioRxiv, 2025.
  • NewsRx. New Solid Cancer Data Have Been Reported by Researchers at University of California (In vivo genome-wide CRISPR screens in human T cells to enhance T cell therapy for solid tumors). Biotech Week. October 29, 2025; p 36.